image
Agilent Technologies, Inc. A
Healthcare - Medical - Diagnostics & Research - NYSE - US
Watchlist
$ 103.59
0.573 %
$ 29.5 B
Market Cap
23.76
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one A stock under the worst case scenario is HIDDEN Compared to the current market price of 104 USD, Agilent Technologies, Inc. is HIDDEN

A Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one A stock under the base case scenario is HIDDEN Compared to the current market price of 104 USD, Agilent Technologies, Inc. is HIDDEN

A Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one A stock under the best case scenario is HIDDEN Compared to the current market price of 104 USD, Agilent Technologies, Inc. is HIDDEN

A Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart A

image
1M -18%
6M -39%
1Y -27%
3Y -22%
5Y 38%
All
$155.0$155.0$150.0$150.0$145.0$145.0$140.0$140.0$135.0$135.0$130.0$130.0$125.0$125.0$120.0$120.0$115.0$115.0$110.0$110.0$105.0$105.0$100.0$100.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
6.51 B REVENUE
-4.73%
Growth Rates
1Year -4.73%
3Years 1.00%
5Years 4.75%
7Years 5.51%
10Years -0.70%
1.49 B OPERATING INCOME
10.22%
Growth Rates
1Year 10.22%
3Years 3.37%
5Years 9.60%
7Years 8.49%
10Years 6.00%
1.29 B NET INCOME
3.95%
Growth Rates
1Year 3.95%
3Years 2.13%
5Years 3.77%
7Years 9.47%
10Years 10.00%
1.75 B OPERATING CASH FLOW
-1.19%
Growth Rates
1Year -1.19%
3Years 5.65%
5Years 11.39%
7Years 10.17%
10Years 9.40%
-1.26 B INVESTING CASH FLOW
-305.81%
Growth Rates
1Year -305.81%
3Years -18.87%
5Years 4.58%
7Years -22.44%
10Years -18.42%
-752 M FINANCING CASH FLOW
19.14%
Growth Rates
1Year 19.14%
3Years -2.61%
5Years -20.26%
7Years -20.66%
10Years -22.73%
1.68 B REVENUE
-1.18%
Growth Rates
1Year -4.73%
3Years 1.00%
5Years 4.75%
7Years 5.51%
10Years -0.70%
376 M OPERATING INCOME
-7.84%
Growth Rates
1Year 10.22%
3Years 3.37%
5Years 9.60%
7Years 8.49%
10Years 6.00%
318 M NET INCOME
-9.40%
Growth Rates
1Year 3.95%
3Years 2.13%
5Years 3.77%
7Years 9.47%
10Years 10.00%
431 M OPERATING CASH FLOW
-10.40%
Growth Rates
1Year -1.19%
3Years 5.65%
5Years 11.39%
7Years 10.17%
10Years 9.40%
-94 M INVESTING CASH FLOW
90.15%
Growth Rates
1Year -305.81%
3Years -18.87%
5Years 4.58%
7Years -22.44%
10Years -18.42%
-180 M FINANCING CASH FLOW
-720.00%
Growth Rates
1Year 19.14%
3Years -2.61%
5Years -20.26%
7Years -20.66%
10Years -22.73%
Balance Sheet Agilent Technologies, Inc.
image
Current Assets 3.96 B
Cash & Short-Term Investments 1.33 B
Receivables 1.32 B
Other Current Assets 1.31 B
Non-Current Assets 7.89 B
Long-Term Investments 175 M
PP&E 1.78 B
Other Non-Current Assets 5.93 B
11.22 %11.18 %11.02 %15.01 %50.09 %Total Assets$11.8b
Current Liabilities 1.9 B
Accounts Payable 540 M
Short-Term Debt 45 M
Other Current Liabilities 1.31 B
Non-Current Liabilities 4.05 B
Long-Term Debt 3.34 B
Other Non-Current Liabilities 708 M
9.08 %22.02 %56.24 %11.90 %Total Liabilities$5.9b
EFFICIENCY
Earnings Waterfall Agilent Technologies, Inc.
image
Revenue 6.51 B
Cost Of Revenue 2.98 B
Gross Profit 3.54 B
Operating Expenses 2.05 B
Operating Income 1.49 B
Other Expenses 199 M
Net Income 1.29 B
7b7b6b6b5b5b4b4b3b3b2b2b1b1b007b(3b)4b(2b)1b(199m)1bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
54.30% GROSS MARGIN
54.30%
Averages
1Year 54.30%
3Years 53.12%
5Years 53.28%
7Years 53.63%
10Years 53.21%
22.86% OPERATING MARGIN
22.86%
Averages
1Year 22.86%
3Years 22.08%
5Years 20.68%
7Years 20.07%
10Years 18.69%
19.80% NET MARGIN
19.80%
Averages
1Year 19.80%
3Years 18.75%
5Years 17.77%
7Years 16.58%
10Years 15.21%
21.85% ROE
21.85%
Averages
1Year 21.85%
3Years 22.24%
5Years 20.78%
7Years 19.06%
10Years 16.80%
10.88% ROA
10.88%
Averages
1Year 10.88%
3Years 11.44%
5Years 10.62%
7Years 9.73%
10Years 8.74%
12.62% ROIC
12.62%
Averages
1Year 12.62%
3Years 13.89%
5Years 12.73%
7Years 11.82%
10Years 10.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Agilent Technologies, Inc.
image
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 1.29 B
Depreciation & Amortization 257 M
Capital Expenditures -378 M
Stock-Based Compensation 129 M
Change in Working Capital 83 M
Others -4 M
Free Cash Flow 1.37 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Agilent Technologies, Inc.
image
Wall Street analysts predict an average 1-year price target for A of $146 , with forecasts ranging from a low of $135 to a high of $165 .
A Lowest Price Target Wall Street Target
135 USD 30.32%
A Average Price Target Wall Street Target
146 USD 41.06%
A Highest Price Target Wall Street Target
165 USD 59.28%
Price
Max Price Target
Min Price Target
Average Price Target
170170160160150150140140130130120120110110100100May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.16% DIVIDEND YIELD
0.248 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.8000.8000.7000.7000.6000.6000.5000.5000.4000.4000.3000.3000.2000.2000.1000.1000.0000.0000.10.10.1320.180.1940.210.10.1150.1150.1320.1490.1640.180.1940.210.2250.2250.2360.2480.10.1150.1490.1640.1640.1940.210.2360.1150.420.1320.460.1320.530.1490.630.1490.660.1640.730.180.570.180.610.1940.400.210.440.2250.450.2250.460.2360.480.2360.240.2480.252015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Agilent Technologies, Inc.
image
Sold
0-3 MONTHS
1.61 M USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
2.74 M USD 2
9-12 MONTHS
2.52 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Fear Creates Fortunes: Grab These 7 Blue-Chip Bargains Today Fear at extremes: Investor and consumer sentiment is near historic lows, signaling a high-probability buying opportunity, historically followed by strong 12-month gains. Economic reality check: Real-time economic indicators show GDP growth of more than 2%, despite widespread recession fears, highlighting a disconnect between sentiment and fundamentals. Inflation truth vs. hype: Real-time data shows inflation is falling, contradicting consumer fears and demonstrating that stagflation panic may be premature. seekingalpha.com - 2 weeks ago
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a. businesswire.com - 3 weeks ago
CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025 SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will. businesswire.com - 4 weeks ago
Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025 SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzing tissue samples, often for dia. businesswire.com - 4 weeks ago
Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Med. businesswire.com - 1 month ago
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusiv. businesswire.com - 1 month ago
Agilent Technologies, Inc. (A) TD Cowen 45th Annual Healthcare Conference (Transcript) Agilent Technologies, Inc. (NYSE:A ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Padraig McDonnell - Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Alright, good. I guess we'll start in a minute or two early here, great day two of the TD Cowen Global Healthcare Conference. seekingalpha.com - 1 month ago
Unlocking Agilent (A) International Revenues: Trends, Surprises, and Prospects Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. zacks.com - 1 month ago
Agilent to Participate in TD Cowen Health Care Conference SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference at 9:50-10:20 a.m. Eastern on Tuesday, March 4, 2025, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a globa. businesswire.com - 1 month ago
Agilent Technologies, Inc. (A) Q1 2025 Earnings Call Transcript Agilent Technologies, Inc. (NYSE:A ) Q1 2025 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Parmeet Ahuja - Vice President of Investor Relations Padraig McDonnell - President and Chief Executive Officer Robert W. McMahon - Senior Vice President and Chief Financial Officer Simon May - President of Life Sciences and Diagnostics Markets Group Angelica Riemann - President of Agilent CrossLab Group Mike Zhang - President of Applied Markets Group Conference Call Participants Rachel Vatnsdal - J.P. seekingalpha.com - 1 month ago
Agilent (A) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Agilent (A) give a sense of how its business performed in the quarter ended January 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Agilent Technologies (A) Q1 Earnings and Revenues Beat Estimates Agilent Technologies (A) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.29 per share a year ago. zacks.com - 1 month ago
8. Profile Summary

Agilent Technologies, Inc. A

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 29.5 B
Dividend Yield 0.16%
Description Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Contact 5301 Stevens Creek Boulevard, Santa Clara, CA, 95051 https://www.agilent.com
IPO Date Nov. 18, 1999
Employees 17900
Officers Mr. Parmeet Ahuja Vice President of Investor Relations Mr. Robert W. McMahon C.M.A. Senior Vice President & Chief Financial Officer Ms. Yvonne Mackie MD of UK & Ireland Operations and Vice President of Human Resources - Europe Mr. Bret M. DiMarco Senior Vice President, Chief Legal Officer, & Secretary Mr. Padraig McDonnell Chief Executive Officer, President & Director Ms. Jenipher E. Dalton Senior Vice President, Chief Quality & Regulatory Officer Dr. Simon May SVice President & President of LDG Mr. Henrik Ancher-Jensen Senior Vice President and President of Order Fulfillment & Supply Chain Mr. Rodney Gonsalves Principal Accounting Officer, Vice President & Corporate Controller Mr. Frederick Schwarz SVice President, Chief Strategy & Corporate Development Officer